Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer’s Disease with Selectivity for the Neurotoxic Form of Tau

TORONTO and CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
May 14, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2019 Results

TORONTO and CAMBRIDGE, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
April 23, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the Think Equity Investor Conference

TORONTO and CAMBRIDGE, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
March 26, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019

TORONTO and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
March 21, 2019 15:13 ET | Source: ProMIS Neurosciences Inc.

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer’s Disease

TORONTO and CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
March 19, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PD™ 2019 Conference

TORONTO and CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
March 15, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

TORONTO and CAMBRIDGE, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
February 21, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors

TORONTO, Ontario and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
February 12, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

Parkinson’s Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development

TORONTO and CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
January 31, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer’s Disease

TORONTO and CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...